You are here

Bioiberica keeps within group “A” of Plan Profarma, thereby certifying their compromise with R&D and production in Spain

28 Apr 2015

Our company was granted “good” qualification within the A Group, the one formed by companies having their own manufacturing and R&D center in Spain 

Barcelona, April 28th, 2015. The PROFARMA Plan of the Ministry of Industry has rated given the “good” rating to Bioiberica, thus giving recognition to its efforts and commitment to R&D in Spain. Our company keeps, for one more year, within the A group, which includes those firms carrying out significant research activity at their own production or R&D Center. 

Bioiberica is a biotech firm specializing in the research, development, production and commercialization of bio-molecules for the pharmaceutical, veterinary and agrochemical industries. In the human healthcare field, we are a leading firm in heparin and osteoarthritis, area in which we are focused on innovation. “At this stage we have projects for the development of biomarkers that could help us to detect osteoarthritis before it manifests itself. We are also researching in cell therapy. Furthermore, we are participating in international observational trials that use Big Data to gain better information about the dimensions and quality of life of patients suffering from that disease”, declared Dr. Josep Vergés, clinical pharmacologists and medical and scientific director at Bioiberica. 

The PROFARMA Plan is a joint initiative of the following ministries: Industry, Tourism and Trade; Healthcare and Social Policies; Science and Innovation. Its aim is to increase the competitiveness of the pharmaceutical industry in Spain through the modernization of its sector and boosting those sectors giving greater added value. 

Related News

23 Jan 2024

On a planet where natural resources are limited and there is increasing concern for the environment, the circular economy has emerged as an innovative and sustainable solution.

16 Oct 2023

We participated in CPHI 2023 in Barcelona, ​​where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.

4 May 2023

They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs